Wednesday, July 8, 2026

Patent intelligence · US

US 10357465

Eutectic formulations of cyclobenzaprine hydrochloride

granted A61KA61K31/135A61K9/1623A61K9/2018
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 86
Patent details — US 10357465
Jurisdiction
US
Status
granted
Grant date
Jul 23, 2019
Expiration
Jul 18, 2039
Claims
14
CPC classes
A61K, A61K31/135, A61K9/1623, A61K9/2018
View on Google Patents ↗

Quick answer

US 10357465 (Eutectic formulations of cyclobenzaprine hydrochloride) is held by TONIX PHARMA LIMITED. Status: granted. Granted Jul 23, 2019. Expires Jul 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/135, A61K9/1623, A61K9/2018, A61P, A61P21/00

More from TONIX PHARMA LIMITED

Related pharmaceutical patents in our USPTO index.

  1. US 12383733

    Iontophoresis-based patch type medicine absorption device

    ROOTONIX Co., Ltd. · Expires Aug 7, 2045

    granted
  2. US 12365879

    Synthetic chimeric poxviruses

    TONIX PHARMA LIMITED · Expires Jul 17, 2045

    granted
  3. US 12304901

    Selective ligands for tau aggregates

    Sentonix, Inc. · Expires May 15, 2045

    granted
  4. US 12156897

    Magnesium-containing oxytocin formulations and methods of use

    TONIX PHARMA LIMITED · Expires Nov 28, 2044

    granted
  5. US 12156864

    Analogs of cyclobenzaprine and amitryptilene

    TONIX PHARMACEUTICALS HOLDING CORP · Expires Nov 28, 2044

    granted
  6. US 12097183

    Pharmaceutical composition for treating migraine

    Tonix Medicines, Inc. · Expires Sep 19, 2044

    granted
  7. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. · Expires Sep 12, 2044

    granted
  8. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    TONIX PHARMA LIMITED · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 10357465?

US 10357465 (Eutectic formulations of cyclobenzaprine hydrochloride) is held by TONIX PHARMA LIMITED. Status: granted. Granted Jul 23, 2019. Expires Jul 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10357465?

TONIX PHARMA LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.

When does US 10357465 expire?

Our index shows an expiration date of Jul 18, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.